



Dependable Partners for
Development with Growth



Who We Are

We (formerly Zandu Chemicals Ltd.) are one of the fastest growing Pharmaceutical companies in India that combines the power of Science & Technology together. Established in 1991, we are headquartered in Mumbai and have a state-of-the-art US FDA successfully inspected facility with a capacity of 214 KL along with strong research & development capabilities strategically located in the industrial park of Ankleshwar, Gujarat.

We are a 100% EOU (Export Oriented Unit) engaged in manufacturing and exports of advanced drug intermediates and Active Pharma Ingredients (APIs). We are a specialized Pharma company focusing on the niche therapeutic areas of CNS, ARVs and Controlled substances having tremendous future growth potential. By virtue of this niche focus we have registered an impressive growth over the years.

Our strategy going forward is to further consolidate our pre-eminent position in the high growth therapeutic areas by expanding our capacity for present advanced intermediates and moving up the value chain by expanding capacity for APIs and diversifying product portfolio into the other high growth therapeutic areas like Anti-diabetic, Anti-coagulants and others.

We are a US FDA, KFDA, WHO-GMP and Japanese MOH accredited company having certifications of ISO 9001, ISO 14001 and OHSAS 18001. We have an integrated SAP system in place.

While over 90% of our revenue is from established markets, we are growing rapidly in the emerging markets. We have an established track record in pharma business with focus on low to medium volume and high value products.



Where we are

- Strategically located in Ankleshwar, GIDC, Gujarat which is 192 miles / 320 km North of Mumbai.
- It is known for its industrial township called GIDC (Gujarat Industrial Development Corporation)


Customer-centric approach

We have spent years creating a culture around the customer and their needs.

Our customer-centric approach has won the status of a preferred supplier/strategic partner from global pharmaceutical innovators and generic companies. We have aligned the entire organization to be decisive and agile that keeps us winning our customers appreciation.

Our commitment is to keep up our tradition of delivering customer value and having our valuable customers in the very heart of our corporate focus.

Geographic and business spread



Manufacturing capabilities

- Four multi-purpose, multi-product cGMP manufacturing units
- Five powder processing areas as per class ISO 8 (Class 100,000)
- Designed to conform to cGMP and approvable by international regulatory bodies (US FDA, EU GMP, PMDA, TGA, ANVISA, WHO)
- Dedicated Cryogenic and Hydrogenation suites
- Reaction Temperature ranging from -78 deg C to +220 deg C
- High vacuum distillation at 1 Torr and high pressure reactions at 20 Bar
- Installed Reaction capacity of 214 KL with 72 reactors - 34 Stainless Steel reactors, 37 Glass Lined reactors, One Cryogenic reactor, ranging from 100 L to 8,000 L
- 22 Centrifuges – Stainless Steel, halar-coated and peeler
- 18 Dryers : RCVD, VTD, FBD, ANFD, TD and Nauta
- Blenders with 0.3–3.0 KL volume<
- Micronizer Air Jet mill and Multi-mill (for particle size reduction)
- Purified water system to meet current USP quality



Chemistry Competence

Expertise in Hydrogenation, Chiral, Asymmetric transformation, Cyclization, Acylation and Alkylation Chemistry.

- Asymmetric transformations
- Azide chemistry
- Alkylations
- Chlorosulfonation
- Couplings (Heck, Stille and others)
- Cyclization/Cyclocondensations
- Enantioselective Hydrolysis
- Epoxidation
- Friedel-Craft acylations
- Grignard
- Halogenation (elemental Br/Cl/I)
- Isomer Separations (conventional optical resolutions)
- Oxidations (Hypochlorite/Per acids)
- Phase Transfer catalysis
- Reductive Amination
- Reductions (Ra-Ni/Pd-C/Pt-C/SnCl₂/Conventional agents)
- Solid distillation (up to 0.01 torr)
- Name Reactions (On scale) - (Dieckmann/Hantzsch/Ritter/Sandmeyer/Ullmann/Willgerodt/Wittig/Several others)

Research & Development

Located in our Ankleshwar facility. State-of-the-art R&D Centre has four furnished labs equipped with some of the latest analytical equipment and managed by experienced scientists and qualified professionals.

- Proven record for developing complex and quality products for big pharma companies worldwide
- Expertise in developing novel Polymorphs and non-infringing process
- Specialization in Controlled substances, CNS, Anti-diabetic and Anti-coagulant molecules
- Collaborative R&D & CMO projects under confidentiality agreement
- Seamless interface with operations resulting in credible deliverance



Quality Management

- Successfully inspected by USFDA and KFDA
- Adherence to ICH Q7A & ISO 9001 quality standards.
- Regular Customer Audits – most of them being global pharmaceutical companies.
- Well-equipped instrumentation labs
- Microbiology lab meeting Schedule M requirements

Active Pharma Ingredients (APIs)

Product	Status	Pharmacopeia	CAS No.	Therapeutic Use
Alprazolam	Tech pack	USP/EP	28981-97-7	Anxiolytic
Aripiprazole	USDMF, CEP+ & WC	USP/EP	129722-12-9	Anti-depressant/Anti-psychotic
Atomoxetine HCl	CEP+, USDMF, TDMF, IDL+ & WC	USP/EP	82248-59-7	Attention Deficit Hyperactivity Disorder (ADHD)
Betahistine Dihydrochloride	CEP, TDMF & WC	USP/BP/EP/IP	5579-84-0	Vertigo
Betahistine Mesylate	Tech pack	EP/JP/IP	54856-23-4	Vertigo
Cilostazol	Tech pack	USP	73963-72-1	Anti-thrombotic, Anti-platelet agent
Clozapine	USDMF*, CEP* & WC*	USP/EP/IP	5786-21-0	Anti-psychotic
Dexmethylphenidate HCl	Tech pack	Inhouse	19262-68-1	Attention Deficit Hyperactivity Disorder (ADHD)
Eslicarbazepine Acetate	Tech pack	In-house/IP	236395-14-5	Anti-epileptic
Felbinac	EDMF*, JDMF* & WC	BP/EP/JP	5728-52-9	Anti-inflammatory
Fluvoxamine Maleate	CEP, USDMF, TDMF & WC	USP/BP/EP/IP	61718-82-9	Anti-depressant
Guanfacine HCl	Tech pack	USP	29110-48-3	Attention Deficit Hyperactivity Disorder (ADHD), Hypertension
Levomepromazine Maleate	CEP* & WC	EP/JP	7104-38-3	Anti-psychotic
Loxoprofen sodium	Tech pack	JP	80382-23-6	Anti-inflammatory, Analgesic
Lurasidone HCl	Tech pack	In-house	367514-88-3	Anti-psychotic
Memantine HCl	USDMF & WC	USP	41100-52-1	Alzheimer Disease
Methylphenidate HCl	Tech pack	USP/EP	298-59-9	Attention Deficit Hyperactivity Disorder (ADHD)
Mirabegron	Tech pack	In-house	223673-61-8	Treatment of overactive bladder
Modafinil	Tech pack	USP/EP	68693-11-8	CNS Stimulant
Olanzapine	USDMF*	USP	132539-06-1	Anti-psychotic
Oxazepam	Tech pack	EP	604-75-1	Anxiolytic
Quetiapine Fumarate	USDMF* & CEP*	USP/EP	111974-72-2	Anti-psychotic
Rivaroxaban	Tech pack	In-house	366789-02-8	Anti-coagulant
Trifluoperazine HCl	Tech pack	USP/BP/EP/IP	440-17-5	Anti-psychotic
Zaltoprofen	KDMF	JP	74711-43-6	Anti-inflammatory
Zonisamide	Tech pack & WC*	USP	68291-97-4	Anti-convulsant

Product Pipeline

Brexiprazole	Under development	in-house	913611-97-9	Antipsychotic
Bromazepam	Under Scale up	EP	1812-30-2	Anxiolytic
Dapagliflozin propanediol monohydrate	Under development	In-house	960404-48-2	Anti-diabetic
Darunavir Ethanolate	Under development	In-house	635728-49-3	Treatment of AIDS and HIV infections
Eluxadolone	Under development	In-house	864821-90-9	Irritable bowel syndrome
Empagliflozin	Under development	In-house	864070-44-0	Anti-diabetic
Phenylephrine	Under development	In-house	59-42-7	Decongestant
Pirfenidone	Under development	In-house	53179-13-8	Anti-Inflammatory / Anti-Rheumatic
Pregabalin	Under development	In-house	148553-50-8	Epilepsy, Neuropathic pain and generalized anxiety disorder.














* Under filing, + Applied, WC = Written confirmation

Disclaimer : Users are responsible for all patent related issue for our offered products.














The therapeutic use shown against each product is indicative only and is not for advertising ZCL products.

Patented Products are available for R&D use as per permitted under 35 USC ¶ 271 (e) (1)

Advanced Intermediates

Product	CAS No.	End Use	Structure
(1H)-7-(4'-bromobutoxy)-3,4-dihydro-2-quinolinone	1297225-34-5	Aripiprazole	
1-(2,3-Dichlorophenyl) Piperazine HCl	119532-26-2	Aripiprazole	
3-(methylamino)-1-phenylpropan-1-ol	42142-52-9	Atomoxetine Fluoxetine Nisoxetine	
N-Benzhydrylpiperazine	841-77-0	Cinnarizine	
Benzenesulfonamide, 4-amino-N-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)	169280-56-2	Darunavir	
Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-,1,1-dimethylethylester	191226-98-9	Darunavir, Fosamprenavir	
N-(1,4-Benzodioxan-2-carbonyl)-piperazine	70918-00-2	Doxazosin	
(10S)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide	104746-04-5	Eslicarbazepine acetate	
10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide	29331-92-8	Eslicarbazepine acetate	
4-Hydroxy-3, 5-dimethyl benzonitrile	4198-90-7	Etravirine	
4,4'-Difluorobenzhydrylpiperazine	27469-60-9	Flunarizine	
(1E)-N-Hydroxy-5-Methoxy-1-(4-Trifluoromethylphenyl)Pentan-1-Imine	61747-22-6	Fluvoxamine	
2-Bromo-4'-benzyloxy-3'-nitroacetophenone	43229-01-2	Formoterol	

Advanced Intermediates

Product	CAS No.	End Use	Structure
2,4-Dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-2-(1-methyl propyl)-3H-1,2,4-triazol-3-one	252964-68-4	Itraconazole	
1-Acetyl-4-(4-hydroxyphenyl) piperazine	67914-60-7	Ketoconazole	
(S)-1-chloro-3-[(4-chloro-E-benzylidene)-amino]-propan-2-ol	1345879-87-9	Linezolid	
2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid	68767-14-6	Loxoprofen Sodium	
1R)-2-[[2-(4-aminophenyl)ethyl]amino]-1-phenylethanol hydrochloride	521284-22-0	Mirabegron	
(1R)-2-[[2-(4-nitrophenyl)ethyl]amino]-1-phenylethanol	223673-34-5	Mirabegron	
2-Methyl-10H-thieno[2,3-b][1,5] benzo diazepine-4-amine HCl	138564-60-0	Olanzapine	
5-methyl-2-(2-nitrophenylamino) thiophene-3-carbonitrile	138564-59-7	Olanzapine	
1-Aminoindan	34698-41-4	Rasagiline	
4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one hydrochloride	898543-06-1	Rivaroxaban	
2-(((5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl)methyl)-1H-isoindole-1,3(2H)-dione	446292-08-6	Rivaroxaban	
N-Isopropyl-4-(4-hydroxyphenyl)-piperazine	67914-97-0	Terconazole	
2-(Trifluoromethyl)-phenothiazine	92-30-8	Trifluoperazine	










Disclaimer : Users are responsible for all patent related issue for our offered products.

The therapeutic use shown against each product is indicative only and is not for advertising ZCL products.







Patented Products are available for R&D use as per permitted under 35 USC ¶ 271 (e) (1)

March 2017

Intermediate for controlled substances

Product	CAS No.	End Use	Structure
1-(2-bromoethyl)-4-ethyl-1,4-dihydro-5H-tetrazol-5-one	84501-67-7	Alfentanil	
N-[1-(benzyl)-4-(methoxymethyl)-4-piperidinyl]-N-phenyl Propanamide oxalate	61086-13-3	Alfentanil & Sufentanil	
N-[(4-methoxymethyl-1-benzyl)-4-piperidinyl]-N-phenyl propanamide monohydrochloride	84255-05-0	Alfentanil & Sufentanil	
N-[4-(methoxymethyl)-piperidine-4-yl]-N-phenyl propanamide monohydrochloride	84196-16-7	Alfentanil & Sufentanil	
Chloromethyl cyclopropane	5911-08-0	Buprenorphine	
Bromomethyl cyclopropane	7051-34-5	Buprenorphine	
N-(1-Benzylpiperidin-4-yl)-N-phenylpropanamide Hydrochloride	5156-58-1	Fentanil	
Methyl 4-(phenyl-propionyl-amino)-piperidine-4-carboxylate HCl	61085-87-8	Remifentanil	
N-[(4-Methoxymethyl)-4-piperidinyl]-N-phenyl propanamide	61086-18-8	Sufentanil	

Methyl Phenidate Series

Product	CAS No.	Structure	Product	CAS No.	Structure
Phenyl-(2-pyridyl acetamide)	7251-52-7		dl-threo ritalinic acid*	19395-41-6	
Phenyl-2-(2'-piperidyl)acetamide	19395-39-2		dl-Threo-Ritalinic acid HCl	1382859-13-3	
Threo phenyl-2-piperidyl acetamide*	50288-62-5		d-threo ritalinic acid hydrochloride*	82993-81-5	

*USDMF available








Disclaimer : Users are responsible for all patent related issue for our offered products.

The therapeutic use shown against each product is indicative only and is not for advertising ZCL products.

Patented Products are available for R&D use as per permitted under 35 USC ¶ 271 (e) (1)

March 2017

Under Scale-up / New Development

Product	CAS No.	End Use	Status	Structure
1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-,2,3,4,6-tetraacetate, (1S)- D-Glucitol	461432-25-7	Dapagliflozin propanediol	Under development	
α -D-Glucopyranoside, methyl 1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, 2,3,4,6-tetraacetate	714269-58-6	Dapagliflozin propanediol	Under development	
2-Chloro-1-Dimethylaminopropane HCl	4584-49-0	Methadone	Under development	
2-(2-[3-(3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl)-3-hydroxy-n-propyl]phenyl)-2-propan-1-ol	142569-70-8	Montelukast	Under scale-up	
1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one	6969-71-7	Trazodone	Under scale-up	
4-Amino-2-fluoro-N-methylbenzamide	915087-25-1	Enzalutamide	Under scale-up	
N-Methyl-2-fluoro-4-(1,1-dimethyl cyanomethyl) aminobenzamide	915087-32-0	Enzalutamide	Under scale-up	

Disclaimer : Users are responsible for all patent related issue for our offered products.

The therapeutic use shown against each product is indicative only and is not for advertising ZCL products.

Patented Products are available for R&D use as per permitted under 35 USC ¶ 271 (e) (1)

March 2017



Environment, Health, Safety & Sustainability (EHS&S)

We aim to use natural resources efficiently and minimize the environmental impacts of our activities and products during their life cycles.

- ISO 14001 and OHSAS 18001 certified facility.
- Multiple effect evaporator and reverse osmosis facility.
- Recycle waste water treatment facility aiming towards ZERO discharge.
- HAZOP studies of processes after development.
- Emergency response measures to control and limit the impact of incidents.
- Compliant with state & local EHS regulations.
- EHS practices approved by global pharmaceutical companies
- Member of EcoVadis, Rx-360 and CDP Supply Chain Program.

We are committed to

Manufacture and supply safe and high quality products to meet customers' needs and expectations.

- Provide comfortable and safe workplace for employees as well as our associates and third party personnel.
- Enhance quality, environment, health and safety standards.
- Strengthen our Corporate Social Obligation (CSO) initiatives.

Registered Office

ZCL Chemicals Ltd.

C Wing, 819-821 , 215 Atrium,
Andheri Kurla Road, Chakala,
Andheri (E), Mumbai- 400093, India

Tel: +91 22 61539999
Fax: +91 22 61539997
Email: enquiries@zclchemicals.com

Manufacturing

ZCL Chemicals Ltd.

Plot No. 3102/B, G.I.D.C.,
Ankleshwar - 393002
Gujarat - India.